You are here: Home: Meet The Professors Vol. 2 2004: Case 7: Select publications

Select publications

Franco S et al. Fulvestrant (FaslodexR) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer: a single-center experience. Breast Cancer Res Treat 2003; Abstract 439.

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

 

Table of Contents Top of Page 

 

Home · Search

Editor's Note
 

Case 1: A 62-year-old woman with ER/PR-positive, HER2-negative, nodenegative multicentric breast cancer (from the practice of Thomas Cartwright, MD)
- Select publications
 
Case 2: A 54-year-old woman seven years after node-positive (6/18),ER-positive, PR-negative infiltrating ductal carcinoma with osteoporosis and postchemotherapy pancytopenia (from the practice of AllanFreedman, MD)
- Select publications
 
Case 3: A 79-year-old woman with ER-positive, PR-negative, HER2-negative metastatic lobular breast cancer and malignant ascites (from the practice of Steven Weiss, MD)
- Select publications
 
Case 4: A 79-year-old woman presenting with a palpable five-centimeter nodepositive (7/10), ER/PR-positive lobular carcinoma (from the practice of Howard Abel, MD)
- Select publications
 
Case 5: A 35-year-old woman with a strong family history of breast cancer with comedo DCIS followed by an infiltrating ductal carcinoma three years later (from the practice of Stephen Grabelsky, MD)
- Select publications
 
Case 6: A 39-year-old woman presenting with locally advanced breast cancer and diffuse bony metastases (from the practice of Rajesh Bajaj, MD)
- Select publications
 
Case 7: A 70-year-old woman with ER-positive, HER2-negative metastatic lobular carcinoma in the bone, liver and soft tissue of the orbit (from the practice of Richard Levine, MD)
- Select publications
 

CME Information
Faculty
Home · Contact us
Terms of use and general disclaimer